Drugs / Fusidic Acid
Fusidic Acid
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01756924 | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00948142 | Aug 2009 → Mar 2010 | skin disease caused by bacterial infection | Arrevus Inc. | Completed | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT06695143 | Apr 2025 → Mar 2027 expected | cutaneous leishmaniasis | Institute of Tropical Medicine, Belgium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06911424 | Mar 2025 → Mar 2026 overdue | bacterial conjunctivitis | Baxis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03395132 | Jul 2018 → May 2019 | atopic eczema | LEO Pharma | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00718315 | Apr 2009 → Jun 2012 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT00986856 | May 2004 → Mar 2005 | impetigo | LEO Pharma | Terminated | Met primary Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT01232231 | Jul 2010 → Apr 2012 | methicillin-resistant staphylococcus aureus infectious disease | Joseph Kim | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT07545187 Comparator | Jun 2025 → Apr 2026 | puerperal infection | Alaa Nadhim Hameed | Completed | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT01113125 Comparator | Mar 2010 → Aug 2014 | keloid | Mette Møller Handrup | Unknown | No outcome recorded |
| Phase 4 | NCT03105505 Comparator | Apr 2017 → Sep 2018 | blepharitis | Barzilai Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fusidic Acid | “Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS...” NCT01232231 ↗12“To assess the validity of in vitro susceptibility-testing of S. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with...” NCT00986856 ↗ “The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.” NCT03395132 ↗ “* Fusidic acid PO 500mg twice daily” NCT02123628 ↗ “* Fusidic Acid : 500mg/8h” NCT05074147 ↗ |
| Known as | CEM-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00948142 ↗ |
| Known as | Fucidin cream | “The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.” NCT03395132 ↗ |
| Known as | Fucithalmic | “comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%)” NCT03105505 ↗ |
| Known as | Verutex | “fusidic acid [Verutex]” NCT00718315 ↗ |
| Route | Topical | “topical, daily for 30 days.” NCT00718315 ↗ |